Candidate sulfonated and sulfated topical microbicides: Comparison of anti-human immunodeficiency virus activities and mechanisms of action

被引:98
作者
Scordi-Bello, IA
Mosoian, A
He, CJ
Chen, YB
Cheng, Y
Jarvis, GA
Keller, MJ
Hogarty, K
Waller, DP
Profy, AT
Herold, BC
Klotman, ME
机构
[1] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA
[2] Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA
[3] Univ Illinois, Dept Pharmacol, Chicago, IL USA
[4] Indevus Pharmaceut Inc, Lexington, MA USA
[5] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA
关键词
D O I
10.1128/AAC.49.9.3607-3615.2005
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Poly(styrene 4-sulfonate), cellulose sulfate, polymethylenehydroquinone, and PRO 2000 are sulfated or sulfonated polymers (SPs) under development as topical microbicides. They are presumed to work through similar mechanisms of action, although to date there has been no extensive comparison of their anti-human immunodeficiency virus activities. To determine whether any of these candidate microbicides offers a potential advantage, their in vitro activities, mechanisms of action, stabilities in biological secretions, and toxicities were compared. All four compounds were found to be active against X4, R5, and dualtropic primary isolates and against X4 and R5 laboratory-adapted strains in CD4(+) T cells, macrophages, and single-coreceptor cell lines. Our single-cycle experiments using pseudotyped virus suggest that all four SPs function at the binding and entry stages of the viral life cycle but differ in degree of postentry effect. Surface plasmon resonance analyses demonstrate that SPs bind to X4 and R5 monomeric glycoprotein 120 with similar high binding affinities. When mixed with cervicovaginal lavage fluid, SPs maintain inhibitory activity at concentrations achievable in formulations.
引用
收藏
页码:3607 / 3615
页数:9
相关论文
共 30 条
[1]   A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity [J].
Baba, M ;
Nishimura, O ;
Kanzaki, N ;
Okamoto, M ;
Sawada, H ;
Iizawa, Y ;
Shiraishi, M ;
Aramaki, Y ;
Okonogi, K ;
Ogawa, Y ;
Meguro, K ;
Fujino, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (10) :5698-5703
[2]  
Bjorndal A, 1997, J VIROL, V71, P7478
[3]   Mouse model of cervicovaginal toxicity and inflammation for preclinical evaluation of topical vaginal microbicides [J].
Catalone, BJ ;
Kish-Catalone, TM ;
Budgeon, LR ;
Neely, EB ;
Ferguson, M ;
Krebs, FC ;
Howett, MK ;
Labib, M ;
Rando, R ;
Wigdahl, B .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (05) :1837-1847
[4]   Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread [J].
Cheshenko, N ;
Keller, MJ ;
MasCasullo, V ;
Jarvis, GA ;
Cheng, H ;
John, M ;
Li, JH ;
Hogarty, K ;
Anderson, RA ;
Waller, DP ;
Zaneveld, LJD ;
Profy, AT ;
Klotman, ME ;
Herold, BC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (06) :2025-2036
[5]   Preliminary safety and acceptability of a carrageenan gel for possible use as a vaginal microbicide [J].
Coggins, C ;
Blanchard, K ;
Alvarez, F ;
Brache, V ;
Weisberg, E ;
Kilmarx, PH ;
Lacarra, M ;
Massai, R ;
Mishell, D ;
Salvatierra, A ;
Witwatwongwana, P ;
Elias, C ;
Ellertson, C .
SEXUALLY TRANSMITTED INFECTIONS, 2000, 76 (06) :480-483
[6]   In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission [J].
Dezzutti, CS ;
James, VN ;
Ramos, A ;
Sullivan, ST ;
Siddig, A ;
Bush, TJ ;
Grohskopf, LA ;
Paxton, L ;
Subbarao, S ;
Hart, CE .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (10) :3834-3844
[7]   A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5 [J].
Dragic, T ;
Trkola, A ;
Thompson, DAD ;
Cormier, EG ;
Kajumo, FA ;
Maxwell, E ;
Lin, SW ;
Ying, WW ;
Smith, SO ;
Sakmar, TP ;
Moore, JP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (10) :5639-5644
[8]   Colposcopic evaluation of a vaginal gel formulation of iota-carrageenan [J].
Elias, CJ ;
Coggins, C ;
Alvarez, F ;
Brache, V ;
Fraser, IS ;
Lacarra, M ;
Lähteenmäki, P ;
Massai, R ;
Mishell, DR ;
Phillips, DM ;
Salvatierra, AM .
CONTRACEPTION, 1997, 56 (06) :387-389
[9]   Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides [J].
Greenhead, P ;
Hayes, P ;
Watts, PS ;
Laing, KG ;
Griffin, GE ;
Shattock, RJ .
JOURNAL OF VIROLOGY, 2000, 74 (12) :5577-5586
[10]   HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 VIRAL-PROTEIN-R (VPR) ARRESTS CELLS IN THE G(2) PHASE OF THE CELL-CYCLE BY INHIBITING P34(CDC2) ACTIVITY [J].
HE, JL ;
CHOE, S ;
WALKER, R ;
DIMARZIO, P ;
MORGAN, DO ;
LANDAU, NR .
JOURNAL OF VIROLOGY, 1995, 69 (11) :6705-6711